Brief: Active Biotech: Safety And Preliminary Activity Of Naptumomab In Combination With Durvalumab Presented At AACR 2023

Active Biotech AB publ

19/04/2023 07:06

April 19 (Reuters) - Active Biotech AB publ  ACTI.ST :
    * SAFETY AND PRELIMINARY ACTIVITY OF NAPTUMOMAB IN
COMBINATION
WITH DURVALUMAB PRESENTED AT AACR 2023
    * RESULTS SHOW THAT NAPTUMOMAB AT RP2D OF 10MCG/KG IN
COMBINATION
WITH DURVALUMAB IS GENERALLY WELL TOLERATED WITH LIMITED
TOXICITY
    * PRELIMINARY RESULTS SHOW PRE-TREATMENT WITH OBINUTUZUMAB
REDUCES
FORMATION OF ADAS AND PRESERVES NAPTUMOMAB PLASMA LEVELS

Source text for Eikon:  ID:nMFN4MrRv0 
Further company coverage:  ACTI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))